Effect of combined intravitreal aflibercept and oral prednisone on punctate inner choroidopathy with recurrent choroidal neovascular membrane

Author: Andre Ayres (Brazil)

Co-authors: Catherine Rezende, Heitor Panetta

Purpose

TO EVALUATE THE SHORT AND INTERMEDIATE EFFECT OF COMBINED THERAPHY WITH INTRAVITREAL AFLIBERCEPT AND ORAL PREDNISONE ON THE RECURRENCE OF CHOROIDAL NEOVACULAR MEMBRANE IN A YOUNG FEMALE PATIENT.

Setting/Venue

THE PATIENT PRESENTS UNILATERAL PUNCTATE INNER CHOROIDOPATHY DISEASE AND THE HISTORY OF THREE CHOROIRAL NEOVASCULAR MEMBRANE ACTIVATION EPISODES.

Methods

THE PATIENT RECEIVED 2 AFLIBERCEPT INTRAVITREAL INJECTIONS – 4 WEEK INTERVAL AND ORAL PREDNISONE (0,5 MG/KG PER DAY INITIALLY FOR 21 DAYS, THEN WEANED BY 10 MG EVERY 7 DAYS). BEST CORRECTED VISUAL ACUITY (BCVA), FUNDUS BIOMICROSCOPY, FLUORESCEIN ANGIOGRAPHY, OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY WERE PERFORMED IN 0, 60 AND 180 DAYS.

Results

AT BASELINE, BCVA ON RIGHT EYE WAS 0,25; HYPERFLUORESCENCE FOVEAL LEAKAGE WAS DETECTED ON FLUORECEIN AGIOGRAPHY, SUBRETINAL HYPERREFLECTIVE DEPOSIT AND RETINAL PIGMENT EPITHELIUM DETACHMENT WERE DETECTED ON OCT SCAN AND CHOROIDAL NEOVASCULARIZATION WAS DETECTED ON OCTA. AT DAY 60, BCVA ON RIGHT EYE WAS 0,8 AND NO ABNORMALITIES WERE SEEN ON FLUORESCEIN AGIOGRAPHY, OCT AND OCTA. RESULTS WERE MAINTAINED ON DAY 180.

Conlusions

COMBINED INTRAVITREAL AFLIBERCEPT AND ORAL CORTICOSTEROID TREATMENT RESULTED IN CHOROIDAL NEOVASCULAR MEMBRANE INACTIVATION 60 AND 180 DAYS AFTER TREATMENT.

Financial Disclosure

NONE

Comments

-